The global market for infusion pumps was valued at $2.3 billion in 2020, a 31.9% decrease from $3.3 billion in 2019. In 2020, the entire landscape of the market shifted as a result of the global COVID-19 pandemic. Despite the challenges presented by COVID-19 to this global market, two companies remain on top and are pushing to achieve even more success. As a result, the market is expected to increase over the forecast period at a CAGR of 8.7% to reach $4 billion.
WHAT ARE INFUSION PUMPS?
Infusion pumps are used for patients who require an infusion of fluids as part of their therapy. These fluids contain medication for disease management, pain control, provision of nutrients to compensate for a deficiency, to facilitate faster recovery, hydration, or for blood replenishment. Infusion pump devices fit into five main categories:
- Large volume pumps
- Syringe pumps
- Patient-controlled analgesia pumps
- Electronic ambulatory pumps
- Disposable ambulatory pumps
Large volume infusion pumps are one of the most common types of pumps and perform well in infusion therapies.
WHAT COMPANIES ARE LEADING THE GLOBAL INFUSION PUMP MARKET?
In 2020, B. Braun was the overall leading player in the global infusion pump market. In terms of specific segments, B. Braun led the syringe pump market. Additionally, the company was the second leader in the large volume pump and the disposable ambulatory pump segments.
Braun focuses heavily on improving and innovating upon their infusion pump product lines, contributing to their overall success. One specific innovation the company has been focusing on is reducing the size and space required by the pump. Previously, B. Braun released its Infusomat® volumetric pump, which was globally available for many years. The company’s most recent version of the device is the Infusomat® Space. This product is a small, lightweight device capable of stacking and placement in small spaces.
In addition to the versatility of previous Infusomat® products, the latest addition is also capable of integration with existing hospital data networks for electronic medical record keeping. Having integrated access also encourages the ability to receive and distribute information surrounding drug libraries and dose calculations. Other product offerings include syringe pumps that are similar in that they are lightweight and usable for a wide range of treatment types.
Becton Dickinson, in 2020, was the second leader in the global infusion pump market. Specifically, Becton Dickinson led the IV infusion pump market with solid footprints in the electronic ambulatory infusion pump market, syringe pump, and PCA pump markets.
One of the dominant product lines offered by the company is the Alaris® line. The product line is a modular system and includes the Alaris™ PC Unit, Alaris™ Pump Module, Alaris™ Syringe Module, Alaris™ PCA Module, Alaris™ Auto-ID Module, and Alaris™ EtCO2. These modules are unique, and each contributes to different market segments. The Alaris™ PC Unit functions as the brain of the modular platform as it requires a connection between all of the other modules. The Alaris® pump device functions as a large volume pump, the Alaris™ Syringe Module functions like a syringe pump, while the Alaris™ PCA Module functions as a patient-controlled anesthesia pump.
In 2017, Becton Dickinson purchased the remaining stake in Caesarea Medical Electronics (CME). After gaining this share, Becton Dickinson established a presence in all of the capital equipment segments, unlike any other top competitor.
INTERESTED IN LEARNING MORE ABOUT THE GLOBAL INFUSION PUMP MARKET?